Radiopharmaceuticals have long been shown to be effective at killing cancers, but often damage healthy cells because they are so toxic. Convergent Therapeutics has developed platform technology that takes advantage of the power of radiopharmaceuticals, but links them to targeting mechanisms, such as monoclonal antibodies and ligands, to deliver them in a precise and highly targeted ways. Its lead experimental therapy is an actinium-linked monoclonal antibody that targets prostate-specific membrane antigen to treat prostate cancer. The ability to use dual targeting mechanisms offers the potential for powerful combinations of radiopharmaceuticals while limiting their toxicities. We spoke to Philip Kantoff, co-founder and CEO of Convergent, about the company’s platform technology for developing next-generation radiopharmaceuticals, how the company targets tumor surface molecules, and how its approach minimizes the toxicity of these therapies.